Inactive Instrument

Analyst Reco. Achieve Life Sciences Inc Nasdaq

Equities

JonesTrading Starts Achieve Life Sciences With Buy Rating, $20 Price Target	Apr. 17	MT
Oppenheimer Adjusts Achieve Life Sciences Price Target to $18 From $21, Maintains Outperform Rating	Dec. 12	MT
Lake Street Adjusts Price Target on Achieve Life Sciences to $19 From $22, Maintains Buy Rating	23-05-31	MT
Oppenheimer Adjusts Achieve Life Sciences Price Target to $17 From $20, Maintains Outperform Rating	23-01-10	MT
Maxim Lowers Price Target on Achieve Life Sciences to $8 From $21, Maintains Buy Rating	22-11-16	MT
Oppenheimer Adjusts Achieve Life Sciences PT to $20 From $27 Given Difficult Current Market Conditions, Maintains Outperform Rating	22-11-15	MT
Oppenheimer Adjusts Price Target on Achieve Life Sciences to $27 From $23, Keeps Outperform Rating	22-04-28	MT
Achieve Life Sciences Says Its Smoking Addiction Treatment Candidate Showed Better Quit Rates Than Placebo in Phase 3 Trial	22-04-27	MT
ACHIEVE LIFE SCIENCES : Alliance Global Partners Starts Achieve Life Sciences at Buy with $25 Price Target	21-10-04	MT
ACHIEVE LIFE SCIENCES : Oppenheimer Initiates Coverage on Achieve Life Sciences With Outperform Rating, $23 Price Target	21-06-23	MT
Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2B Orca-1 Dose-Selection Trial	19-06-11	CI

No results for this search